Screener
GeneDx Holdings WGS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by GeneDx Holdings in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001818331-26-000041
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Net cash provided by financing activities | 38,590 | 13,718 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (11,073) | 14,492 |
| Cash, cash equivalents and restricted cash, at beginning of period | 105,989 | 86,202 |
| Cash, cash equivalents and restricted cash, at end of period | $94,916 | $100,694 |
| Supplemental disclosures of cash flow information | ||
| Cash paid for interest | $1,748 | $1,600 |
| Cash paid for taxes | $754 | $206 |
| Lease liability from obtaining right-of-use asset | $12,086 | — |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is GeneDx Holdings's cash & equivalents?
- GeneDx Holdings (WGS) reported cash & equivalents of $94.92M in Q1 2026.
- How has GeneDx Holdings's cash & equivalents changed year-over-year?
- GeneDx Holdings's cash & equivalents decreased by 5.7% year-over-year, from $100.69M to $94.92M.
- What is the long-term trend for GeneDx Holdings's cash & equivalents?
- Over 5 years (2020 to 2025), GeneDx Holdings's cash & equivalents has grown at a -2.3% compound annual growth rate (CAGR), from $118.96M to $105.99M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about GeneDx Holdings's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude